Advertisement

Blueprint Medicines Inks Deal With Roche Worth Up to $1.7 Billion

Blueprint Medicines Inks Deal With Roche Worth Up to $1.7 Billion

Blueprint Medicines (NASDAQ: BPMC) announced Tuesday that global biopharma giant Roche Holdings (OTC: RHHBY) is paying up to $1.7 billion in upfront cash and potential milestones, plus royalties, to obtain commercial rights to market pralsetinib outside the U.